What to Do When Humana Denies Wegovy: Appeal Strategy

Introduction

Humana’s book of business is heavily weighted toward Medicare Advantage and Medicare Part D, which means most Humana Wegovy® denials hit the same wall: Medicare Part D does not cover Wegovy for weight loss. Coverage for Wegovy under Medicare only opened up in March 2024 under the cardiovascular indication after the FDA approved Wegovy for CV risk reduction.

That changes the appeal strategy entirely. If you’re on a Humana Medicare plan, the appeal should usually pivot to the cardiovascular indication, not the obesity indication. If you’re on a Humana commercial plan, the standard PA criteria apply, with the same five-element checklist most commercial plans use.

CMS data from 2023 shows roughly 41 percent of commercial denials and about 38 percent of Medicare Part D denials are overturned on internal appeal when patients submit new clinical documentation. The cardiovascular indication has become the strongest single lever for overturning Humana Part D denials in 2026.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

Why Does Humana Deny Wegovy?

Three denial reasons cover roughly 90 percent of Humana Wegovy rejections. First, the Medicare Part D weight-loss exclusion: Wegovy is not covered for obesity under Part D. Second, prior authorization criteria not met for the cardiovascular indication, usually because the prescriber didn’t document established CVD. Third, on commercial plans, the typical PA criteria failures (BMI, lifestyle program, step therapy).

Quick Answer: Humana’s Medicare Part D plans cover Wegovy only for the cardiovascular indication, not for weight loss

Read your denial letter and find the reason code. Humana Part D denials usually cite the Medicare Part D weight-loss exclusion as the primary reason. Commercial denials cite specific PA criteria failures.

If you have established CVD (prior MI, ischemic stroke, or symptomatic PAD), the appeal should pivot to the cardiovascular indication. Your prescriber’s documentation needs to lead with the CVD diagnosis and ICD-10 codes, not the BMI.

What Is Humana’s 2026 Prior Authorization for Wegovy?

For Humana commercial plans, the 2026 PA criteria for Wegovy require five things: BMI of 30 or higher, or BMI 27 to 29.9 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, OSA, CVD), documentation of a structured weight management program for at least 6 months in the past 24 months, prescriber attestation that lifestyle changes alone have been inadequate, age 18 or older, and concurrent reduced-calorie diet and physical activity.

For Humana Medicare Part D plans, the cardiovascular indication criteria are the only viable path: established CVD (prior MI, ischemic stroke, or symptomatic PAD) with ICD-10 documentation, plus BMI of 27 or higher. The 6-month lifestyle program requirement is waived under the CV pathway on Part D plans.

The most common single fix on commercial denials is missing chart notes proving the 6-month weight management program. On Part D denials, the most common fix is documenting the CVD diagnosis with ICD-10 codes.

How Do I File a Level-1 Internal Appeal with Humana?

For commercial plans, you have 180 days from the denial date to file a level-1 internal appeal. For Medicare Part D plans, you have 60 days. The submission goes to the address on the denial letter, typically a Humana Pharmacy Appeals address in Louisville, Kentucky.

The appeal packet should include a signed appeal letter from you, a Letter of Medical Necessity signed by your prescriber, chart notes from the past 12 months, BMI and weight history, documentation of the 6-month weight management program (for commercial plans), and prior medication trials with dates and outcomes. For Part D appeals, include ICD-10 codes for the CVD diagnosis and any cardiology consultation notes.

Humana has 7 days to respond on a Part D standard appeal and 72 hours on an expedited Part D appeal. Commercial appeals get 30 days for standard and 72 hours for expedited.

What Should the Letter of Medical Necessity Say?

The LMN is the single most important document. It should be on prescriber letterhead, signed and dated, and limited to two pages.

For commercial plans, hit five points. Current BMI and weight, plus BMI trend over 24 months. Comorbidities with ICD-10 codes. Prior weight-loss interventions with dates and outcomes. Clinical rationale citing STEP 1 (Wilding et al. 2021, NEJM) showing 14.9 percent weight loss at 68 weeks, and SELECT (Lincoff et al. 2023, NEJM) showing 20 percent MACE reduction. A statement that lifestyle modifications alone have not produced sustained clinical response.

For Part D plans, the LMN structure changes. Lead with the CVD diagnosis and ICD-10 codes. Cite SELECT (Lincoff et al. 2023, NEJM) directly. State that the request is “for cardiovascular risk reduction per FDA-approved indication based on SELECT trial,” not for weight loss.

What Clinical Evidence Does Humana Respect?

Humana’s pharmacy and therapeutics committee references specific trials when updating coverage policy. Citing those trials by name puts your appeal in their internal vocabulary.

For Wegovy, the strongest 2026 references are SELECT (Lincoff et al. 2023, NEJM) showing 20 percent MACE reduction in 17,604 patients with established CVD, STEP 1 (Wilding et al. 2021, NEJM) for obesity, STEP-HFpEF (Kosiborod et al. 2023, NEJM) for heart failure with preserved ejection fraction, and FLOW (Perkovic et al. 2024, NEJM) showing 24 percent reduction in kidney disease progression and CV death.

For Part D appeals, SELECT is the only trial that matters because it is the basis for the FDA’s CV indication and CMS’s Part D coverage update. Lead with SELECT. Other trials are supporting evidence.

Key Takeaway: About 38 to 41 percent of Humana denials are overturned at level-1 internal appeal with new documentation (CMS 2023)

What If the First Appeal Is Denied?

For commercial plans, you can file a level-2 internal appeal within 60 days, and pursue external review through your state commissioner in parallel.

For Part D plans, the next step after the level-1 redetermination is an independent reconsideration through MAXIMUS (the CMS-contracted Part D IRE). You have 60 days from the Part D level-1 denial to request reconsideration. MAXIMUS has 7 days to respond on standard and 72 hours on expedited.

Beyond MAXIMUS, Part D appeals continue through an Administrative Law Judge hearing (60 days), Medicare Appeals Council review (60 days), and federal district court (60 days). Most successful Part D Wegovy appeals are resolved at level-1 or level-2 with documentation of established CVD.

How Does the SELECT Cardiovascular Indication Change the Appeal?

For Medicare Part D, the SELECT indication is the only viable appeal pathway. CMS clarified in 2024 that Wegovy is covered under Part D when prescribed for the cardiovascular indication, following the FDA’s March 2024 approval. The Part D weight-loss exclusion does not apply when Wegovy is prescribed for CV risk reduction.

Your LMN should explicitly state “requested for cardiovascular risk reduction per FDA-approved indication based on SELECT trial.” Cite Lincoff et al. 2023 NEJM. Document established CVD with ICD-10 codes (I21.x for prior MI, I63.x for ischemic stroke, I70.2 for symptomatic PAD). BMI of 27 or higher must also be documented.

For commercial appeals, the CV indication is a parallel pathway with relaxed PA criteria. Use it when applicable.

What If My Humana Plan Carves Out Weight-loss Drugs?

For Humana commercial plans, employer carve-outs of weight-loss drugs cannot be appealed because the benefit comes from the plan document. The CV indication may be covered separately on some self-funded plans because it is a cardiovascular benefit, not an obesity benefit. Ask HR.

For Humana Medicare Part D plans, weight-loss coverage is structurally excluded by CMS, not by Humana. There is no plan-level carve-out to appeal. The CV indication remains the only viable pathway.

Cash-pay options include the Novo Nordisk NovoCare savings card (for commercially-insured patients only, not Medicare patients), the NovoCare Pharmacy direct cash program at about $499 per month, and compounded semaglutide through a licensed telehealth platform like TrimRx with a free assessment quiz.

How Long Does the Appeal Process Take?

For commercial plans, a standard level-1 internal appeal takes 30 days, level-2 takes 30 days, and external review takes 45 days. Total: 4 to 5 months end to end.

For Medicare Part D, level-1 redetermination takes 7 days, MAXIMUS reconsideration takes 7 days, ALJ hearing takes up to 90 days, MAC review takes up to 90 days, and federal court can take a year or more. Most Part D appeals are resolved at level-1 or MAXIMUS reconsideration within a few weeks.

Expedited appeals on both commercial and Part D can compress timelines to 72 hours per level when prescribers attest to urgent medical need.

Bottom line: You have 60 days to file a Part D appeal and 180 days for commercial appeals

FAQ

Can I Appeal a Humana Wegovy Denial Without My Doctor’s Help?

Possible but rare to succeed. The Letter of Medical Necessity from the prescriber carries clinical authority that a patient letter cannot match. Most prescribers will write one if you ask in writing and provide the denial letter.

Does Humana Cover Wegovy for Medicare Patients with Diabetes?

Only for the cardiovascular indication. Type 2 diabetes alone does not qualify for Medicare Part D Wegovy coverage. Established CVD must be documented. If a patient has both type 2 diabetes and CVD, the CVD documentation drives the coverage. Ozempic® remains covered for type 2 diabetes under Part D.

What ICD-10 Codes Does Humana Want for the CV Indication?

I21.x (acute MI history), I22.x (subsequent MI), I25.2 (old MI), I63.x (cerebral infarction history), I69.3 (sequelae of cerebral infarction), I70.2 (atherosclerosis of native arteries of extremities with intermittent claudication or rest pain), Z86.71 (personal history of venous thrombosis and embolism), and Z95.x (presence of cardiac or vascular implants).

How Much Does Wegovy Cost Without Humana Coverage?

Brand-name Wegovy lists at approximately $1,349 per month. The NovoCare savings card can drop the cost to $0 to $25 for eligible commercially-insured patients (Medicare patients are not eligible). The NovoCare Pharmacy direct cash program offers Wegovy at about $499 per month for cash-pay patients.

Can I Switch to Compounded Semaglutide If the Appeal Fails?

Yes. Compounded semaglutide from a licensed 503A pharmacy is the same active ingredient as Wegovy, prescribed through telehealth platforms like TrimRx after a clinical assessment. Costs run roughly $199 to $399 per month depending on dose. Compounding is legal when prescribed for an individual patient based on clinical need.

What Is MAXIMUS and When Do I Use It?

MAXIMUS is the CMS-contracted independent review entity for Medicare Part D appeals. After your level-1 redetermination is denied by Humana, you have 60 days to request reconsideration by MAXIMUS. MAXIMUS is an independent reviewer outside the plan and applies CMS coverage criteria directly. Many Part D appeals succeed at this level after the plan denies.

Can I Get an Expedited Appeal If I Have a Recent MI?

Yes. A recent myocardial infarction within the past 12 months is one of the strongest justifications for an expedited appeal. Your prescriber must attest that delay in starting Wegovy would jeopardize cardiovascular health based on the SELECT trial outcomes data.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.